罗晓颖,张凤如,何汝敏,戚文航.参附注射液辅助治疗缺血性心肌病伴心功能不全的疗效评价[J].中国中西医结合杂志,2009,(8):685-687 |
参附注射液辅助治疗缺血性心肌病伴心功能不全的疗效评价 |
Efficacy of Shenfu Injection as Adjuvant Therapy in Treating Patients of Ischemic Cardiomyopathy with Heart Insufficiency |
免费下载全文 查看/发表评论 下载PDF阅读器 |
|
DOI: |
中文关键词: 参附注射液 缺血性心肌病 心功能不全 |
英文关键词:Shenfu Injection ischemic cardiomyopathy heart insufficiency |
基金项目: |
|
摘要点击次数: 1374 |
全文下载次数: 5 |
中文摘要: |
目的评价参附注射液辅助治疗缺血性心肌病伴心功能不全的临床疗效。方法将入选100例缺血性心肌病伴心功能不全患者随机分为参附组和常规组各50例,参附组在常规组治疗基础上每月靜脉滴注参附注射液10天(每天1次,每次60mL),疗程6个月。观察治疗前后心功能分级、6min步行距离、心脏超声指标和血浆N端脑钠肽前体(pro-BNP)水平的变化以及心血管事件发生率和病死率。结果参附组对心功能分级和6min步行距离的改善作用较常规组显著(P<0.05);常规治疗基础上加用参附注射液能进一步缩小左心室舒张和收缩末期内径,增加左心室射血分数(P<0.05),降低血浆N端pro-BNP水平;参附组心血管事件发生率显著低于常规组(P<0.05)。结论在常规治疗基础上加用参附注射液能改善缺血性心肌病伴心功能不全患者的心功能、提高生活质量、改善心室重构,减少心血管事件发生。 |
英文摘要: |
Objective To evaluate the clinical efficacy of Shenfu Injection (SFI),as a adjuvant therapy,in treating patients of ischemic cardiomyopathy with heart insufficiency (ICP-HI). Methods One hundred patients of ICP-HF were equally randomized into two groups,the SFI group and the control group. All received the conventional treatment,but to patients in the SFI group SFI was given additionally via intravenous injection,60 mL once a day,10 days each month,the treatment course was 6 months. Changes of cardial functional grading,6-min walking distance,echocardiographic indices,plasma N terminal pro-brain natriuretic peptide(pro-BNP) level were observed before and after treatment,and the occurrence of major adverse cardiovascular events (MACE) and mortality in patients were observed as well. Results As compared with the conventional treatment alone,additional application of SFI showed a more significant efficacy in improving NYHA functional grade and 6-min walking distance,reducing the diameters of left ventricular at end diastole and systole,increasing left ventricular ejection fraction,and decreasing plasma N terminal pro-BNP level (P<0.05). The occurrence of MACE and the mortality in the SFI group were significantly lower than those in the control group respectively (P<0.05). Conclusions Based on the conventional treatment,the adjuvant therapy of SFI could improve the cardiac function,improve the quality of life,ameliorate ventricular reconstruction,and decrease the occurrence of cardiovascular events in patients of ICP-HI. |
关闭 |
|
|
|